This study focuses on severe eosinophilic asthma, a serious form of asthma characterized by high levels of specific white blood cells called eosinophils. The research examines a medication called dexpramipexole, which is given as a film-coated tablet that patients take by mouth. The purpose is to evaluate the long-term safety and how well patients tolerate this treatment when taken over an extended period.
The study is a continuation of previous research and will involve patients who have already completed earlier phases of testing this medication. During the study, participants will take dexpramipexole tablets twice daily for up to 52 weeks. The medication aims to help control the symptoms of severe asthma and reduce the number of asthma attacks.
Throughout the study, researchers will monitor how the treatment affects participants’ asthma control, including how often they experience severe asthma attacks. They will also track changes in the levels of eosinophils in the blood and assess how well patients can manage their asthma symptoms. Regular check-ups will be conducted to monitor the participants’ overall health and any effects of the medication.
Bulgaria 
Czechia 
Germany 
Italy 
Poland 
Romania 
Spain 
